Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Intra-lesion administration of an Endothelin Receptor B inhibitor (BQ-788) or vehicle was
preformed in 5 melanoma patients to have a preliminary analysis of safety, dose, duration and
relevance of results observed in pre-clinical studies to the human disease.
Phase:
Early Phase 1
Details
Lead Sponsor:
MelCure SA
Collaborators:
California Institute of Technology Universitaire Ziekenhuizen Leuven University of Bern